Global Regulatory Standards for Visual Inspection of Injectable Drug Products

Visual inspection of injectable and parenteral drug products is governed by a network of pharmacopoeial standards, GMP guidelines, and regulatory agency guidance documents. This page provides a practical reference guide to the key standards applicable to injectable manufacturers globally – what each standard covers, who it applies to, and where to access the official source.

Trusted by
90+ Drug Manufacturers Globally

United States — FDA & USP Standards

Standard

Title

What it covers

Official Source

USP <790>

Visible Particulates in Injections

Compendial acceptance standard for injectable products. Defines the requirement that products be ‘essentially free’ of visible particulates. Specifies AQL sampling procedure (General Level II, AQL 0.65%) and the inspection conditions (illumination, backgrounds, timing). This is the mandatory standard — it defines pass/fail criteria.

USP.org

USP <1790>

Visual Inspection of Injections

Comprehensive guidance on how to build, validate, and maintain a compliant visual inspection process. Covers inspector qualification and Probability of Detection (PoD) studies, inspection lifecycle management, AVI system qualification, DIP product strategies, defect categorisation, and requalification frequency. Guidance chapter — not compendial standard but represents FDA expectation

USP.org

USP <1207>

Package Integrity Evaluation — Sterile Products

Guidance for Container Closure Integrity Testing (CCIT) methods including vacuum decay, pressure decay, and high-voltage leak detection. References laser-drilled containers as calibrated reference standards for leak test equipment qualification.

USP.org

21 CFR Part 211

Current Good Manufacturing Practice for Finished Pharmaceuticals

FDA’s cGMP regulation. Sections 211.68, 211.84, and 211.111 address in-process and finished product inspection requirements. Requires that injectable products be inspected for visible particulates, defects, and container integrity.

US Code of Federal Regulations (eCFR)

21 CFR Part 11

Electronic Records and Electronic Signatures

Applies to electronic records and audit trails in regulated pharmaceutical environments. Relevant to AVI systems and inspection booths that capture electronic data, calibration logs, and inspection records. VIB-300 is 21 CFR Part 11 compliant.

US Code of Federal Regulations (eCFR)

FDA Guidance (August 2023)

Inspection of Injectable Products for Visible Particulates: Guidance for Industry

Risk-based, holistic guidance on visible particulate control. Clarifies that meeting USP <790> alone is not sufficient – manufacturers must demonstrate effective process controls, investigation capability, and requalification frequency. Emphasizes that visual detection is a probabilistic process. Finalized in August 2023, replacing the 2022 draft.

FDA.gov — Guidance for Industry

European Union — EMA & Ph. Eur. Standards

Standard

Title

What it covers

Official Source

EU GMP Annex 1 (2022)

Manufacture of Sterile Medicinal Products

The primary EU GMP standard for sterile manufacturing. Section 8 addresses visual inspection — mandates 100% inspection of all injectable units, inspector qualification, documented inspection procedures, and a Contamination Control Strategy (CCS) that encompasses particulate risk. The 2022 revision significantly strengthened particulate control expectations.

European Medicines Agency (EMA)

Ph. Eur. 2.9.20

Visible Particles (Particulate Contamination: Visible Particles)

European Pharmacopoeia equivalent of USP <790>. Defines the acceptance requirement that parenteral solutions be ‘practically free from particles’. Specifies inspection conditions and AQL sampling procedures.

European Pharmacopoeia (EDQM)

Ph. Eur. 5.17.2

Recommendations on Testing of Particulate Contamination

Guidance on particulate contamination testing methods for parenteral products, including visible particle testing procedures.

European Pharmacopoeia (EDQM)

EU GMP Annex 11

Computerised Systems

Applies to all forms of computerized systems used as part of GMP-regulated activities. Crucial for Automated Visual Inspection (AVI) systems, electronic data storage, and audit trail compliance in the EU. Replaces 21 CFR Part 11 under the EU section.

European Commission / EMA

MHRA Guidance

Rules and Guidance for Pharmaceutical Manufacturers and Distributors (Orange Guide)

UK’s pharmaceutical manufacturing guidance post-Brexit. Largely mirrors EU GMP requirements for visual inspection of sterile products. Applicable to manufacturers supplying the UK market.

UK MHRA

Japan — PMDA & JP

Standard

Title

What it covers

Official Source

JP <6.06>

Foreign Insoluble Matter Test for Injections

Japanese Pharmacopoeia test for visible particulate matter in injectable products. Aligns with the fundamental requirement that no visible foreign particles are present in injectable products. Equivalent in principle to USP <790> and Ph. Eur. 2.9.20.

Japanese Pharmacopoeia (MHLW)

PMDA GMP Guidance

Pharmaceuticals and Medical Devices Agency — GMP Compliance

Japan’s regulatory agency for pharmaceutical manufacturing. GMP inspections align with ICH Q10 and the Pharmaceutical Affairs Act. Injectable manufacturers exporting to Japan must demonstrate visual inspection compliance with JP standards.

Pharmaceuticals and Medical Devices Agency (PMDA)

International - WHO & ICH

Standard

Title

What it covers

Official Source

WHO TRS 1019, Annex 2 (2019)

WHO Good Manufacturing Practices for Sterile Pharmaceutical Products

WHO GMP for sterile products, including requirements for 100% visual inspection of injectable units. Applicable to manufacturers supplying WHO-prequalified markets including low- and middle-income countries. Replaces the outdated TRS 986 Annex 6 citation.

World Health Organisation (WHO)

ICH Q9(R1)

Quality Risk Management

Quality risk management framework used in defect classification (critical, major, minor) and particulate risk assessment for injectable products. The revised R1 version (finalized January 2023) places stronger emphasis on reducing subjectivity in quality risk assessments.

ICH

ICH Q10

Pharmaceutical Quality System

International Council for Harmonisation standard for pharmaceutical quality systems. Establishes the framework for process performance monitoring, which includes visual inspection trending and particulate contamination control as ongoing quality activities.

ICH

India - CDSCO

Standard

Title

What it covers

Official Source

CDSCO Schedule M (Revised)

Good Manufacturing Practices for Pharmaceutical Products

India’s primary GMP standard under the Drugs and Cosmetics Act. Schedule M (Revised) aligns more closely with WHO and ICH GMP expectations, including requirements for visual inspection of injectable products, batch release testing, and documentation standards.

CDSCO

Australia - TGA

Standard

Title

What it covers

Official Source

TGA / PIC/S GMP  Guide (PE009)

Australian Code of Good Manufacturing Practice for Medicinal Products

Mirrors EU GMP requirements. Australia officially adopts the PIC/S Guide to GMP (PE009), and the TGA inspects Australian and overseas manufacturers supplying the Australian market. Visual inspection requirements for injectable products follow EU GMP Annex 1 expectations.

TGA / PIC/S

Industry Technical Reports

Standard

Title

What it covers

Official Source

PDA Technical Report No. 43

Influence of Packaging on the Visual Inspection of Parenteral Products

Addresses the impact of glass, plastic, and elastomeric components on visual inspection, container defects, and particulate detection, establishing baseline methodologies for inspection planning. This is the correct, highly relevant technical report for packaging effects on visual detection.

PDA

PDA Technical Report No. 79

Particulate Matter Control in Biopharmaceuticals

Foreign particle risk management for biologics manufacturers. Details risk-based particulate control, root-cause investigations, and probability of detection (PoD) validation for visual inspection systems.

PDA

ISPE Baseline Guide

Sterile Manufacturing Facilities

Facility design guidance including visual inspection area layout, lighting specifications, and ergonomics requirements to minimise inspector fatigue and optimise defect detection.

PDA

Trusted by Leading Pharma Companies

Hear directly from pharmaceutical professionals who trust our solutions to deliver quality, reliability, and performance.

"SSG is a one-stop solution for all visual inspection needs. From particulate defects, size verification, and source validation to kit preparation and seamless handover, their expertise is evident. The SSG team truly understands pharma regulations and acknowledge the importance of setting industry standards.“

Dr. Reddy's Laboratories Ltd.

"We really appreciate all of your support in getting our Manual Visual Inspection Defect Kits ready for qualifying our inspectors. You've been right there, helping wherever and whenever needed for the past few months. From ordering supplies to supervising the set-up of the supply - we are grateful for your timely support and for providing all required documents for regulatory audits. We are honored by your assistance and look forward to continuing our collaboration"

PAR Pharma

"SSG is a one-stop solution for all visual inspection needs - from particulate defects and sizing to certification and kit handover. The execution was seamless, and the team demonstrated a deep understanding of pharma regulatory requirements. The documentation provided fully meets compliance standards. We're pleased to see an Indian supplier offering high-quality standard defect kits with proper regulatory documentation. Delivery was on time, and service support has been excellent. I highly recommend Siddhi Sai to anyone planning to procure defect kits"

Zydus Lifesciences Ltd. (SEZ Onco Injectable)

“Exceptional support for technical clarifications, with prompt responses to particle adhesion issues. The team ensures thorough follow-ups until resolution and provides additional samples swiftly when required”

Biocon, Bangalore, India

“Reliable and prompt support at all times. The team provides excellent assistance and is highly recommended for Knapp kits and defect kits”

STERIL-GENE, Pondicherry, India

"We procured the known particle size kit for both vials and PFS from SSG. The quality of the units was excellent, and the response and support from the SSG team were outstanding. I highly recommend SSG to anyone looking for a reliable known particle kit supplier."

BE Pharmaceuticals

"We procured a particle size kit for vials from the SSG team and received exceptional service. The timely delivery and extended support in designing particles for the injectable process enabled us to qualify our inspection process on schedule. Thank you, SSG team!“

Mankind Pharma, Paonta Sahib, H.P., India